Trademark applications and grants for Axsome Therapeutics Inc. Axsome Therapeutics Inc has 32 trademark applications. The latest application filed is for "AGAINST THE GRAINE"
Patent Application | Date |
---|---|
REBOXETINE TO TREAT NARCOLEPSY 20220280524 - 17/751490 Tabuteau; Herriot | 2022-09-08 |
DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION 20220257538 - 17/728554 Tabuteau; Herriot | 2022-08-18 |
USE OF ESREBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS SUCH AS FIBROMYALGIA 20220249501 - 17/536669 Tabuteau; Herriot | 2022-08-11 |
DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION 20220249406 - 17/731247 Tabuteau; Herriot | 2022-08-11 |
DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION 20220249405 - 17/730015 Tabuteau; Herriot | 2022-08-11 |
NCAGE Code | 7J7H1 | AXSOME THERAPEUTICS INC |
CAGE Code | 7J7H1 | AXSOME THERAPEUTICS INC |
SEC | 0001579428 | Axsome Therapeutics, Inc. of DELAWARE |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.